In Defense of Antimicrobial Prophylaxis for Prevention of Infective Endocarditis in Patients With Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology

Volumn 54, Issue 24, 2009, Pages 2339-2340

  Maron, Barry J ^a   Lever, Harry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL ENDOCARDITIS; CLINICAL PRACTICE; EMBOLISM; EXERCISE; HEART FUNCTION; HEART OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LETTER; MITRAL VALVE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REST;

ANTIBIOTIC PROPHYLAXIS; CARDIOMYOPATHY, HYPERTROPHIC; ENDOCARDITIS, BACTERIAL; HUMANS;

EID: 70649103177     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.050     Document Type: Letter

References (10)

1. Bach D.S. Perspectives on the American College of Cardiology/American Heart Association guidelines for the prevention of infective endocarditis. J Am Coll Cardiol 53 (2009) 1852-1854
2. Wilson W., Taubert K.A., Gewitz M., et al. Prevention of infective endocarditis guidelines from the American Heart Association. A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 16 (2007) 1736-1754
3. Jones T.D., Baumgartner L., Bellows M.T., et al., Committee on Prevention of Rheumatic Fever and Bacterial Endocarditis, American Heart Association. Prevention of rheumatic fever and bacterial endocarditis through control of streptococcal infections. Circulation 11 (1955) 317-320
4. Dajani A.S., Bisno A.L., Chung K.J., et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 264 (1990) 2919-2922
5. Dajani A.S., Taubert K.A., Wilson W., et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 277 (1997) 1794-1801
6. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol 42 (2003) 1687-1713
7. Roberts W.C., Kishel J.C., McIntosh C.L., Cannon III R.O., and Maron B.J. Severe mitral or aortic valve regurgitation, or both, requiring valve replacement for infective endocarditis complicating hypertrophic cardiomyopathy. J Am Coll Cardiol 19 (1992) 365-371
8. Spirito P., Rapezzi C., Bellone P., et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 99 (1999) 2132-2137
9. Alessandri N., Pannarale G., del Monte F., Moretti F., Marino B., and Reale A. Hypertrophic obstructive cardiomyopathy and infective endocarditis: a report of seven cases and a review of the literature. Eur Heart J 11 (1990) 1041-1048
10. Maron M.S., Olivotto I., Zenovich A.G., et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114 (2006) 2232-2239